PTH and hypercalcemia disease: Even at a saturation dose for suppressing the tonic pools of PTH (Fig. 7B), aducanumab reversed aging-induced hypercalcemia to serum calcium levels only slightly higher than those in 3-month-old vehicle-treated mice (Fig. 7C).